TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06309342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREVFUNKTION
Description: Functional profile and advice concerning cardiovascular fitness level, strength, mobility, balance and posture. Motivational interview and support in goalsetting to make lifestyle changes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Physical activity measured with accelerometers. Functional examination. Medical examination and advice concerning weight measures, blood pressure and standard blood tests.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Physical activity measured with accelerometers. Functional examination. Medical examination and advice concerning weight measures, blood pressure and standard blood tests.
Study: NCT05737784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-222 - Initial Dose
Description: PRAX-222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-222 - Initial Ascending Doses
Description: Ascending doses of PRAX-222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-222 - Optional Ascending Doses
Description: Escalation of PRAX-222 dose(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-222 - Fixed Doses
Description: Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-222 - Fixed Doses
Description: Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo procedure

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo procedure

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo procedure
Study: NCT06628726

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Description: surgical biopsy from liver
Study: NCT06630520

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular injection
Description: A 50ml periarticular injection was introduced intraoperatively before the time of closing. The injection contained 150mg bupivacaine (3mg/mL), 60mg ketorolac(1.2mg/mL) and 1mg morphine.~Before wound closure, periarticular cocktail was injected around the knee joint including the adductor canal from the hamstring harvest side in PAI group. All patients had oral paracetamol 500mg, 4 times/day and diclofenac 75mg, 1 times/day after surgery.
Study: NCT06629194

Intervention type: DIAGNOSTIC_TEST
Intervention: interferon gamma releasing assay (IGRA)
Description: All patients who suspected CD or TB will be tested for interferon-gamma releasing assay. An interferon-gamma release assay is a blood test that measures the body\&#39;s immune response to Mycobacterium tuberculosis, the bacteria that causes tuberculosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: interferon gamma releasing assay (IGRA)
Description: All patients who suspected CD or TB will be tested for interferon-gamma releasing assay. An interferon-gamma release assay is a blood test that measures the body\&#39;s immune response to Mycobacterium tuberculosis, the bacteria that causes tuberculosis.
Study: NCT06629636

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NMN capsule
Description: Total of 900mg/day for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NMN-free placebo capsules for 8 weeks
Study: NCT06629909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretome
Description: 3 ml Injection of secretome for 8 times two weeks apart
Study: NCT06629337

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)
Description: Subjects ingested fexofenadine (540 mg, tablet) at least 50 minutes before and famotidine (40 mg, tablet) 1 hour 50 minutes before the onset of each protocol because these dose of oral fexofenadine and famotidine reaches its peak concentration at around 1 h and 2 h, respectively

Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)
Description: Subjects ingested fexofenadine (540 mg, tablet) at least 50 minutes before and famotidine (40 mg, tablet) 1 hour 50 minutes before the onset of each protocol because these dose of oral fexofenadine and famotidine reaches its peak concentration at around 1 h and 2 h, respectively
Study: NCT06628583

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging with Contrast
Description: The study was retrospective and did not set interventions

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging with Contrast
Description: The study was retrospective and did not set interventions
Study: NCT06631014

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Early Rehab
Description: The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Rehab
Description: The 2nd group of 25 patients that was fitted with Prosthesis after the time period of 6months after amputation. No physical rehab was done during this time period including physiotherapy and prosthetic treatment. Main aim was to check the significant impact of delayed rehabilitation.
Study: NCT06631898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SaaTwae Bio-Natural Moisturizing Cream
Description: A 0.04 gm of test products along with controls (negative and positive) will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
Study: NCT05784688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218 + Pembrolizumab
Description: TU2218: Orally administered Pembrolizumab: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218 + Pembrolizumab
Description: TU2218: Orally administered Pembrolizumab: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218 + Pembrolizumab
Description: TU2218: Orally administered Pembrolizumab: Intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218 + Pembrolizumab
Description: TU2218: Orally administered Pembrolizumab: Intravenously administered
Study: NCT06713200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High intensity percutaneous electrolysis
Description: A sterile, disposable stainless steel needle of different lengths depending on the area to be treated will be connected to the EP device; the gauge of these needles will be 0.25 mm. A current of 3 mA will be applied for 3 times with a duration of 3 seconds each. In order to avoid biases, the technique will be performed for 90 seconds as in the low intensity treatment group and in the last 20 seconds the current will be applied with the parameters previously described. Three sessions divided in three consecutive weeks will be applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity Percutaneous Electrolysis
Description: This technique will be performed with the same instrument as the high intensity technique. It differs from the previous treatment group in that the current intensity in this case will be of an amperage of 0.3mA during 90 seconds. In the same way, 3 sessions divided in 21 consecutive days will be applied.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simulated Percutaneous Electrolysis
Description: The needle and PD device will be connected in the same way as for the other treatment groups. The needle will be inserted without reaching the lesion area and the characteristic sound of turning on the PD machine will be made. It will last 90 seconds and at no time the galvanic current will be applied. The same aseptic precautions will be applied, in addition to performing the same final hemostasis guidelines and providing the same post-treatment guidelines as for all the other subjects in the study.
Study: NCT05946824

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily-adaptive Stereotactic Body Radiation Therapy
Description: Daily-adaptive radiation therapy to two dose levels - one to the area of radiologic recurrent nodal disease, and a lower, prophylactic dose to the standard post-prostatectomy and larger pelvic node fields

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily-adaptive Stereotactic Body Radiation Therapy
Description: Daily-adaptive radiation therapy to two areas - a high dose to the area of radiologic recurrence, and a lower, prophylactic dose to the standard post-prostatectomy fields
Study: NCT03306615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection
Study: NCT06157853

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Microneedling
Description: A fractional bipolar radiofrequency microneedling device will be performed at Visit 2, after the 7-day washout period. Subjects were numbed 45 minutes prior to RF microneedling with topical numbing Benzocaine 20%/Lidocaine 6%/tetracaine 4%. Bony areas, periorbital, forehead, and chin were treated with 15 watts at a 2 mm needle depth on cycle mode. All subjects received 20 watts at 3 mm depth on cycle mode on soft tissue, neck, and cheeks.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency Microneedling
Description: A fractional bipolar radiofrequency microneedling device will be performed at Visit 2, after the 7-day washout period. Subjects were numbed 45 minutes prior to RF microneedling with topical numbing Benzocaine 20%/Lidocaine 6%/tetracaine 4%. Bony areas, periorbital, forehead, and chin were treated with 15 watts at a 2 mm needle depth on cycle mode. All subjects received 20 watts at 3 mm depth on cycle mode on soft tissue, neck, and cheeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Cleanser
Description: Facial cleanser to be used by subjects twice-daily. This product was used during the entire 14-day study (7-day washout period and 7-day post-procedure timeline).

Intervention type: OTHER
Group type: OTHER
Intervention: Facial Cleanser
Description: Facial cleanser to be used by subjects twice-daily. This product was used during the entire 14-day study (7-day washout period and 7-day post-procedure timeline).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: Bland moisturizer to be used by subjects twice daily during the 7-day washout period. Use 1 to 2 pumps and place all over face and avoid the eye area.

Intervention type: OTHER
Group type: OTHER
Intervention: Facial Moisturizer
Description: Bland moisturizer to be used by subjects twice daily during the 7-day washout period. Use 1 to 2 pumps and place all over face and avoid the eye area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Bland sunscreen to be used by subjects after cleansing and the facial moisturizer during the 7-day washout period. Bland sunscreen to be used by subjects after cleansing and after the active post-procedure cream and comparator anhydrous cream. Use the provided sunscreen and reapply as needed throughout the day and per recommendation of the FDA, every 2 hours.
Study: NCT05139160

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein quality
Description: the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein quality
Description: the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.
Study: NCT05822895

Intervention type: DEVICE
Intervention: CADe enabled programme (GI Genius)
Description: CADe enabled programme (GI Genius)
Study: NCT05625386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).
Study: NCT06553612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment
Description: Delivery of a personalized post-cancer plan with multidisciplinary assessment of oncology support care needs in a day hospital

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard assesment
Description: Delivery of a personalized post-cancer plan without a day hospital

Intervention type: OTHER
Group type: OTHER
Intervention: Observational cohort
Description: Patients with no cancer sequelae, no adverse effects and no need for oncological support care will not be randomized, but will be followed as part of an observational cohort
Study: NCT06307665

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BDA MDI
Description: Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: AS MDI
Description: Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
Study: NCT05624749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ianalumab
Description: ianalumab s.c. monthly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo s.c. monthly
Study: NCT05139160

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein quality
Description: the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.
Study: NCT05779722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapor barrier
Description: Vapor barrier
Study: NCT05605743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
Study: NCT04878042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Description: Mouth wash and nasal spray 3 times a day for 3 days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth wash and nasal spray 3 times a day for 3 days
Study: NCT05657912

Intervention type: DEVICE
Intervention: ECG monitoring
Description: Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
Study: NCT05520827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04902586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTFields
Description: The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.
Study: NCT06631950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: The educational intervention group will be provided with information that should allow them to correctly answer questions on fecundity knowledge and fecundity risks factors. The fecundity information will be provided through a short animated educational video (3 minutes) that will be sent out digitally. The control group is not receiving such information.
Study: NCT06631612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric hydroxide polymaltose complex
Description: participants will receive oral iron supplementation according to body weight every other day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric hydroxide polymaltose complex
Description: participants will receive oral iron supplementation dose according to body weight daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole.
Description: both arms will receive Albendazole 400mg once at the beginning f the study to be repeated after 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole.
Description: both arms will receive Albendazole 400mg once at the beginning f the study to be repeated after 1 week
Study: NCT06628375

Intervention type: OTHER
Intervention: Consultation visit (Visit 1)
Description: During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the diagnosis of hypospadias, as a part of routine care. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty and then, another sample in a 5 ml EDTA tube will be taken for DNA collection.

Intervention type: OTHER
Intervention: Consultation visit (Visit 1)
Description: During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the absence of hypospadias. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty.
Study: NCT06630637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose-Ketone Index (GKI) monitoring
Description: Ketone and blood glucose monitoring with Abbott Optium Neo up to 10 times per day to observe GKI dynamics for gamification of adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Description: Monitoring with an Abbott Freestyle Libre to observe glucose dynamics for gamification of adherence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital dynamometer
Description: Grip strength measurements, right and left hand, up to 20 readings per day per hand.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearables
Description: All Apple Watch 9 and Whoop data daily \[heart rate variability (HRV), resting heart rate, cardio recovery, sleep duration, composition (stages of sleep) and analogous scores, potential maximum rate of oxygen consumption attainable during physical exertion (VO2 max), basal metabolic rate and potential respiratory rate\].
Study: NCT05058664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-F texting component
Description: Over the course of the 6-week intervention parents in the A-F condition will receive 1 message each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-F texting component
Description: Over the course of the 6-week intervention parents in the A-F condition will receive 1 message each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-F texting component
Description: Over the course of the 6 week intervention, parents will receive between 1-2 messages, depending on randomization (in addition to A-F component messages)
Study: NCT05516901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The erector spinae plane block group
Description: The probe should then slowly be moved laterally until the transverse process is visible. The 100 mm, 25-gauge needle should be inserted using an in-plane approach in the cephalad to caudal direction and advanced under ultrasound guidance towards the transverse process; once the needle tip is below the erector spinae muscle, a small bolus of local anesthetic should be given. The erector spinae muscle should be visualized, separating from the transverse process. After aspiration the local anesthetic (20 ml of 0.25% bupivacaine was injected. Technique was repeated on the other side.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Patients in this group will receive general anesthesia alone.
Study: NCT06630637

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood tests
Description: Pre- and Post-fast (48h) testing of lipid panel, ApoB, ApoA1, CRP, interleukin panel, omega 3:6 ratio, and autophagy analysis. Potential CBC, renal and liver panels to be taken where appropriate.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool tests
Description: 15 g of stool will be collected from the subject pre- and post-fast for microbiome assessment and pre- and post- the first week (the three meal phase). After the first week, the maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva tests
Description: Saliva samples will be collected from the subject pre- and post-fast for microbiome assessment. Maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast).